Extended indication Treatment for the Prevention of Attacks in patients with Type I and II Hereditary Angioedema
Therapeutic value No judgement
Registration phase Registration application pending

Product

Active substance Berotralstat
Domain Chronic immune diseases
Reason of inclusion New medicine (specialité)
Main indication Other chronic immune diseases
Extended indication Treatment for the Prevention of Attacks in patients with Type I and II Hereditary Angioedema
Manufacturer BioCryst
Mechanism of action Other
Route of administration Oral
Therapeutical formulation Capsule
Budgetting framework Extramural (GVS)
Additional comments Bradykinine remmer

Registration

Registration route Centralised (EMA)
Submission date April 2020
Expected Registration May 2021
Orphan drug Yes
Registration phase Registration application pending
Additional comments Datum indiening en verwachte registratie op basis van actual primary completion date van fase 3 studie in April 2019.

Therapeutic value

Current treatment options C1-esteraseremmers en icatibant en Cinryze. Daarnaast ook de monoklonale antistof lanadelumab.
Therapeutic value No judgement
Substantiation De verwachting is dat berotralstat (oraal) de concurrentie aan zal gaan met lanadelumab (subcutaan). Het zal met name ingezet worden ter preventie.
Frequency of administration 1 times a day
Dosage per administration 150 mg
References NCT03485911

Expected patient volume per year

Patient volume

< 350

Market share is generally not included unless otherwise stated.

References Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B, HAWK (Hereditary Angioedema International Working Group). Allergy. 2012 Feb; 67(2):147-57.
Additional comments Hereditair angio-oedeem heeft een prevalentie van 1 op de 50.000. Dit zou betekenen dat er maximaal 350 patiënten in Nederland in aanmerking komen voor deze behandeling. De verwachting is dat een gedeelte van de patiënten mogelijk zal overstappen van lanadelumab op berotralstat.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No
References Adis Insight
Additional comments Geen nieuwe indicaties in de pijplijn

Other information

There is currently no futher information available.